Peptides & Metabolic Research: GLP-1, Tirzepatide & Retatrutide — Literature Analysis
Summary
The category of peptides connected with metabolic research has expanded significantly in recent years. From classic GLP-1 agonists (Semaglutide) to dual (Tirzepatide) and triple agonists (Retatrutide, Cagrilintide+Semaglutide), the literature offers increasingly detailed clinical data. Growth-hormone analogues such as AOD-9604 are also studied. This guide analyzes the position of each molecule in the literature.
Substance Properties
Why are GLP-1 peptides connected with metabolic research?
GLP-1 (glucagon-like peptide-1) is a gut hormone secreted after food intake that signals satiety in the brain, slows gastric emptying and regulates blood glucose. GLP-1 agonists mimic this action with longer duration. This mechanism explains why they are the subject of intensive clinical research in obesity and type 2 diabetes.
Semaglutide — the most documented
Semaglutide has extensive STEP clinical-trial data and is considered the benchmark molecule in the category. In Greece and Cyprus it is available as an approved medicinal product (Ozempic, Wegovy) in prescription context. For literature background, see Semaglutide research overview.
Tirzepatide — dual agonist with stronger data
Tirzepatide (Mounjaro/Zepbound), as a dual GLP-1/GIP agonist, has strong SURMOUNT clinical-trial data in prescription context. The comparison with Semaglutide is discussed in the SURMOUNT-5 study (2025), always as a literature reference and not as a therapeutic recommendation.
Retatrutide — triple agonist under research
Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon agonist in Phase 3 development. The TRIUMPH-4 study records strong metabolic endpoints in the literature. For educational analysis, see Retatrutide TRIUMPH-4. It remains investigational with no approved use.
AOD-9604 — GH fragment and lipolysis
AOD-9604 is a fragment of the human growth hormone sequence (amino acids 177-191) studied specifically for lipolytic properties without the anabolic effects of HGH. In experimental models it shows selective activity in adipose tissue. It should not be confused with approved anti-obesity medicines. See AOD-9604 for educational context.
Cagrilintide + Semaglutide — dual action
The CagriSema combination (Cagrilintide + Semaglutide) combines an amylin analogue with a GLP-1 agonist. The REDEFINE 1 study (2024) is an important clinical-trial reference for metabolic research. For educational analysis, see Cagrilintide + Semaglutide.
Related Guides
Frequently Asked Questions (FAQ)
Which molecules have the most mature clinical data?
Semaglutide and Tirzepatide have the most mature clinical data as approved medicinal products. Retatrutide shows strong Phase 3 data but remains investigational.
How should metabolic endpoints be read?
Clinical-study endpoints are literature data from specific populations and protocols. They are not a promise of outcome or instructions for use.
Are these peptides available in Greece?
Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro) are available as approved prescription medicines. The others (Retatrutide, AOD-9604) are not approved medicinal products.
Does this guide provide medical advice?
No. It is exclusively an educational overview of the research literature. Any therapeutic decision requires a physician.
References & Studies
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023.
- Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide. Lancet. 2021.
Disclaimer
This article is exclusively educational. It does not constitute medical advice, treatment recommendation, or instructions for human use. Approved medicines require a prescription and medical supervision.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer